Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study
Eva Prescott, Oskar Angerås, David Erlinge, Erik L Grove, Marja Hedman, Lisette O Jensen, John Pernow, Antti Saraste, Axel Åkerblom, Sara Svedlund, Anna Rudvik, Jane Knöchel, Eva-Lotte Lindstedt, Pavlo Garkaviy, Li-Ming Gan, Anders Gabrielsen
Dyk ned i forskningsemnerne om 'Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction: The phase 2a FLAVOUR study'. Sammen danner de et unikt fingeraftryk.